A study by LexisNexis Risk Solutions shows a significant increase in gender identity diagnoses, eating disorders, and phobic disorders in minors from 2019 to 2023. Meanwhile, the rise of appetite-suppressing drugs like Ozempic is attributed to social media, with ongoing research on their effects.
#Ozempic: A Double-Edged Sword for #WomensHealth and Equity https://t.co/XyyyDqSaPU https://t.co/vEsvXvOIEZ
Interesting from @dcdx_co: Survey of 1K+ Gen Z on Ozempic and weight-loss drugs: 83% had a negative perception - and yet GLP-1 prescriptions for 12-25 y/o's are up 600%. The rise of Ozempic - and its knock-offs - is reminiscent of the SHEIN paradox.
Interesting from @dcdx_co: Survey of 1K+ Gen Z on Ozempic and weight-loss drugs: 83% had a negative perception - and yet GLP-1 prescriptions for 12-25 y/o's are up 600% The rise of Ozempic - and its knock-offs is reminiscent of the SHEIN paradox.
A new study finds that people who had higher obesity and lost more weight while taking a drug like Ozempic were the most likely to lose even more weight during the 12 months after stopping the drug. https://t.co/wOk9CRR99s
Over 250 people who took the weight loss drugs Ozempic, Wegovy and semaglutide self-reported depression and other more severe side effects to the FDA. An Atlanta man shares his story of what happened when he took the drugs. https://t.co/G9Yl924jVM https://t.co/GMIkI4dIQu
The search for lean mass loss with semaglutide, an observational study https://t.co/E8gUrbDqOY #T2D #obesity
Ozempic and Mounjaro makers could be hit with 10,000 lawsuits over claims the drugs cause life-threatening side effects | Daily Mail Online https://t.co/NqIjZaJCBC
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan' https://t.co/qBC3ulMadm
Scams tied to Ozempic and other new weight-loss drugs are surging. How to protect yourself https://t.co/q79ifyVi3q
The Mystique of #Ozempic Is Growing ā¦@TheAtlanticā© https://t.co/GAZCq1Q09P
The diagnoses for gender dysphoria has gone up but the actual cases have not. It's medical hysteria, driven largely by pharmaceutical companies and activists, both of whom stand to gain financially. https://t.co/DvNVl5OapV
Could weight loss drugs such as Wegovy open up new ways to treat depression, anxiety, addiction and even Alzheimer's? https://t.co/WhkLzRORg3
Ozempic, Wegovy scams skyrocket as demand surges for expensive weight loss drugs https://t.co/x1tOgWMTUD
News Roundup: Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss https://t.co/yGm1ArUxhG
Ozempic and Mounjaro makers could be hit with 10,000 lawsuits over claims the drugs cause life-threatening side effects https://t.co/yEhLIlJ8mh https://t.co/5NqELxnrEY
One in eight American adults have used popular weight loss and diabetes drugs known as GLP-1 agonists, according to the latest KFF Health Tracking Poll.
A surge in gender dysphoria diagnoses after the Covid-19 pandemic coincided with a similar rise in eating disorder referrals. @elizamondegreen reports on a new study š https://t.co/HesdgzTfLu
GLP-1 weight-loss drugs don't just fight obesity. There may be benefits for heart & kidney disease, Alzheimer's, some cancers, even compulsive behaviors. Some of those probably won't pan out but still, pretty amazing. @yeahyeahyasmin in @TheAtlantic https://t.co/zobMaHZCBU
In a few years from now, what will be the most important therapeutic indication(s) for GLP-1 medicines and how might that work? @yeahyeahyasmin @TheAtlantic surveys the landscape beyond #obesity #T2D #heartdisease https://t.co/m4LNB6uona
Gender dysphoria diagnoses rose by 133% among children and adolescents between 2019 and 2023. We are not interrogating the psychological impact of the pandemic, writes @elizamondegreen š https://t.co/HesdgzTfLu
Metabolic benefits on the liver in preclinical studies with glucagon-GLP-1R co-agonism beyond #weightloss https://t.co/LT9Kgct2AF @imperialcollege https://t.co/rjU6RlzyIV
Social media has helped fuel theĀ riseĀ of appetite-suppressing drugs like Ozempic, but as the medication trends online, it's important to remember that scientists areĀ still learningĀ about these novel medicationsĀ in real-time. https://t.co/i021bQgGNE
In @BioCentury's Clinical Report: Shionogi mulling next steps in obesity after underwhelming readout; updates from Bluejay and Vir in HDV; Skye's ophthalmic miss; and more https://t.co/69BsK8KHgh
The @Verily plan- helping patients reach their weight goals ā and then weaning them off of GLP-1s #obesity #heartdisease #T2D https://t.co/7XxqmGjWMv
NEWS: Rx For Gender Dysphoria In kids doubles 2019-2023 LexisNexis Risk Solutions looked at data on >300M patients, found these trends of new diagnoses in minors 2019-2023: ā¶ļøGender identity diagnoses, up 133% ā¶ļøEating disorders, up 108% ā¶ļøPhobic disorders, up 77% Plus:ā¦ https://t.co/cAFntVwQbs